Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
HR
Heron Therapeutics, Inc.
HRTX
Mkt Cap
$69.7M
Volume
1.63M
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
HR
HRTX
HR
Heron Therapeutics, Inc.
HRTX
News
·
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Mkt Cap
$71.5M
Volume
1.63M
Next Earnings
November 3rd
Chart
Financials
Earnings
News
About
Insider
Filings
Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors
Heron Therapeutics announced the appointment of Thomas Cusack to its Board of Directors, effective October 27, 2025. Cusack brings over 20 years of investment management and corporate finance experience, most recently serving as a Managing Director at Starboard Value LP.
GlobeNewswire Inc. · Oct 29, 2025
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Heron Therapeutics, a commercial-stage biotechnology company, will host a conference call on November 12, 2024, to report its third quarter 2024 financial results and discuss recent business highlights.
Benzinga · Oct 29, 2024
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
The global chemotherapy-induced nausea and vomiting treatment market is expected to grow at a CAGR of 6.4% and reach a valuation of US$ 12,688.0 million by 2034, driven by the increasing incidence of cancer and the need for effective management of CINV.
GlobeNewswire Inc. · Sep 17, 2024
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
Merck (MRK) exercises the option that will convert the collaboration deal with partner Orion for prostate cancer candidate opevesostat into a license agreement.
Zacks Investment Research · Jul 2, 2024
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
Zacks Investment Research · Jul 1, 2024
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.
Zacks Investment Research · Jun 27, 2024
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Zacks Investment Research · Jun 26, 2024
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
Ionis Pharmaceuticals (IONS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks Investment Research · Jun 25, 2024
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
Zacks Investment Research · Jun 24, 2024
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
Two late-stage studies, which evaluated Ovid Therapeutics' (OVID) experimental drug for two forms of epilepsy, fail to meet their primary endpoints.
Zacks Investment Research · Jun 18, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
HR
HRTX
Heron Therapeutics, Inc.
Buy
Sell
Market
Limit
Soon
HRTX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any HRTX yet.
Related Tickers
Earnings